First Patients Vaccinated in Clinical Trial of Experimental HIV Vaccine

Dr. David Diemert, director of The GW Vaccine Research Unit, was interviewed on CTV Your Morning about our current clinical trial of an experimental HIV vaccine.

“The future implications are huge if we could have an effective HIV vaccine that would prevent people from getting the infection and thereby not having to go on antiretroviral medication for the rest of their lives,” he says.

Latest News

This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.
This was a phase 1, double-blind trial to examine the safety and immunogenicity of a replication-competent recombinant vesicular stomatitis virus-vectored vaccine to reduce the risk of infection and severe illness from Lassa Fever.
The GW VRU is pleased to share the findings from a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection. This study adds to the evidence that matching COVID-19 vaccines to the circulating…